iHuman Inc. Logo

iHuman Inc.

IH

(3.2)
Stock Price

1,57 USD

13.19% ROA

21.61% ROE

5.53x PER

Market Cap.

1.012.409.140,58 USD

0.45% DER

0% Yield

17.8% NPM

iHuman Inc. Stock Analysis

iHuman Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

iHuman Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (21.33%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Net Profit Growth

This company's net profit has consistently grown over the last five years, indicating a strong financial performance and making it an attractive investment opportunity.

5 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

6 PBV

The stock's PBV ratio (1.14x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

7 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-451.002) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

iHuman Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

iHuman Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

iHuman Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

iHuman Inc. Revenue
Year Revenue Growth
2018 131.867.000
2019 218.656.000 39.69%
2020 531.915.000 58.89%
2021 944.722.000 43.7%
2022 985.517.000 4.14%
2023 1.045.984.000 5.78%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

iHuman Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 52.103.000
2019 170.155.000 69.38%
2020 199.510.000 14.71%
2021 415.334.000 51.96%
2022 313.481.000 -32.49%
2023 264.672.000 -18.44%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

iHuman Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 13.986.000
2019 189.433.000 92.62%
2020 114.667.000 -65.2%
2021 97.445.000 -17.67%
2022 109.195.000 10.76%
2023 104.280.000 -4.71%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

iHuman Inc. EBITDA
Year EBITDA Growth
2018 -21.698.000
2019 -278.214.000 92.2%
2020 -44.451.000 -525.89%
2021 -54.248.000 18.06%
2022 111.582.000 148.62%
2023 161.572.000 30.94%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

iHuman Inc. Gross Profit
Year Gross Profit Growth
2018 66.013.000
2019 134.493.000 50.92%
2020 365.443.000 63.2%
2021 660.624.000 44.68%
2022 691.174.000 4.42%
2023 746.500.000 7.41%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

iHuman Inc. Net Profit
Year Net Profit Growth
2018 -17.604.000
2019 -275.597.000 93.61%
2020 -37.476.000 -635.4%
2021 -37.051.000 -1.15%
2022 109.819.000 133.74%
2023 207.664.000 47.12%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

iHuman Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 0
2019 -6 100%
2020 -1 0%
2021 -1 0%
2022 0 0%
2023 4 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

iHuman Inc. Free Cashflow
Year Free Cashflow Growth
2018 -5.033.000
2019 40.236.000 112.51%
2020 207.080.000 80.57%
2021 5.931.000 -3391.49%
2022 187.128.250 96.83%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

iHuman Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 -4.504.000
2019 42.627.000 110.57%
2020 222.986.000 80.88%
2021 38.214.000 -483.52%
2022 189.592.000 79.84%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

iHuman Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 529.000
2019 2.391.000 77.88%
2020 15.906.000 84.97%
2021 32.283.000 50.73%
2022 2.463.750 -1210.32%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

iHuman Inc. Equity
Year Equity Growth
2018 -63.735.000
2019 -14.449.000 -341.1%
2020 642.653.000 102.25%
2021 608.371.000 -5.64%
2022 769.452.000 20.93%
2023 928.347.000 17.12%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

iHuman Inc. Assets
Year Assets Growth
2018 58.599.000
2019 168.315.000 65.18%
2020 1.046.945.000 83.92%
2021 1.100.881.000 4.9%
2022 1.333.399.000 17.44%
2023 1.411.838.000 5.56%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

iHuman Inc. Liabilities
Year Liabilities Growth
2018 122.334.000
2019 182.764.000 33.06%
2020 404.292.000 54.79%
2021 492.510.000 17.91%
2022 563.947.000 12.67%
2023 483.491.000 -16.64%

iHuman Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
19.5
Net Income per Share
3.47
Price to Earning Ratio
5.53x
Price To Sales Ratio
0.98x
POCF Ratio
5.34
PFCF Ratio
5.41
Price to Book Ratio
1.09
EV to Sales
-0.02
EV Over EBITDA
-0.12
EV to Operating CashFlow
-0.11
EV to FreeCashFlow
-0.11
Earnings Yield
0.18
FreeCashFlow Yield
0.18
Market Cap
1,01 Bil.
Enterprise Value
-0,02 Bil.
Graham Number
37.07
Graham NetNet
14.24

Income Statement Metrics

Net Income per Share
3.47
Income Quality
1.97
ROE
0.22
Return On Assets
0.13
Return On Capital Employed
0.21
Net Income per EBT
0.85
EBT Per Ebit
1.12
Ebit per Revenue
0.19
Effective Tax Rate
0.15

Margins

Sales, General, & Administrative to Revenue
0.11
Research & Developement to Revenue
0.25
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.7
Operating Profit Margin
0.19
Pretax Profit Margin
0.21
Net Profit Margin
0.18

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0.01
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
3.59
Free CashFlow per Share
3.55
Capex to Operating CashFlow
-0.01
Capex to Revenue
-0
Capex to Depreciation
-0.24
Return on Invested Capital
0.17
Return on Tangible Assets
0.13
Days Sales Outstanding
25.33
Days Payables Outstanding
19.47
Days of Inventory on Hand
16.14
Receivables Turnover
14.41
Payables Turnover
18.75
Inventory Turnover
22.62
Capex per Share
-0.05

Balance Sheet

Cash per Share
22,26
Book Value per Share
17,60
Tangible Book Value per Share
17.6
Shareholders Equity per Share
17.6
Interest Debt per Share
-0.14
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-5.84
Current Ratio
2.79
Tangible Asset Value
0,90 Bil.
Net Current Asset Value
0,86 Bil.
Invested Capital
0
Working Capital
0,86 Bil.
Intangibles to Total Assets
0.02
Average Receivables
0,07 Bil.
Average Payables
0,02 Bil.
Average Inventory
14300500
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

iHuman Inc. Dividends
Year Dividends Growth

iHuman Inc. Profile

About iHuman Inc.

iHuman Inc. provides intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Reading, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, and iHuman Readers. It also provides intellectually stimulating materials, including books, interactive materials, and smart devices that develop children's abilities in speaking, critical thinking, independent reading, and creativity. The company was founded in 1996 and is based in Beijing, the People's Republic of China.

CEO
Mr. Peng Dai
Employee
770
Address
Building 2
Beijing, 100102

iHuman Inc. Executives & BODs

iHuman Inc. Executives & BODs
# Name Age
1 Mr. Wenbin Lu
Chief Technology Officer
70
2 Ms. Weiwei Wang
Chief Financial Officer & Director
70
3 Mr. Peng Dai
Chief Executive Officer & Director
70
4 Mr. Yufeng Chi
Founder & Chairman
70

iHuman Inc. Competitors